Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Antibe Therapeutics Inc.

04 Mar 2021 02:00 AM

04 Mar 2021 01:59 AM

12 Mar 2019 03:05 AM <--

Return to Antibe Therapeutics Inc.

Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a growth trajectory in the dental biologics market.

http://www.antibethera.com